pipette
ENEnglish

The intestinal microbiome shapes responses to the GD2/GD3 cancer vaccine in children with high-risk neuroblastoma

L. Ma, K. Argyropoulos, K. Dhuri, N. Waters, T. Fei, I. Y. Cheung, X. Wu, Y. Zhang, L. Babiker, K. Lederer, L. Harford, N. Brijmohan, C. Nguyen, K. Victor, J. Yang, A. Dai, J. Peled, A. Hanash, S. R. Roberts, J. J. Boelens, S. Nierkens, G. Diehl, K. A. Markey, Y. Taur, M. da Silva, B. Kushner, I. Maillard, R. Govind, N.-K. Cheung, M. van den Brink, S. Modak, O. Miltiadous

PreprintUso en el mundo real

En palabras de los autores

The intestinal microbiome influences vaccine responses, but its role in therapeutic cancer vaccination remains largely unexplored. We investigated the gut microbiome, vaccine immunogenicity and clinical outcomes in 137 children with high-risk neuroblastoma receiving GD2/GD3 vaccination with oral b-glucan. Microbiome-perturbing antibiotic exposure was associated with inferior progression-free survival (PFS). Among patients vaccinated in first remission, higher a-diversity and enrichment of Lachnospiraceae, including Blautia, were associated with higher anti-GD2 IgG1 responses, while higher Clostridia abundance was associated with superior PFS. Patients had microbiome profiles resembling those of chronologically younger healthy children, consistent with delayed microbiome maturation. A greater discrepancy between patients' chronological age and the age of microbiome-matched healthy children was associated with inferior PFS among patients in first remission. In a complementary mouse model, antibiotic treatment impaired vaccine-induced anti-GD2 IgG responses and accelerated tumor growth. Together, these findings support a role for the intestinal microbiome in therapeutic cancer vaccine responses and identify microbiome maturation as a clinically relevant feature in pediatrics.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 18 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.16.766479